Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

With Antegren Launch Expected, Biogen Idec Tops 2Q Estimates

July 29, 2004

By Aaron Lorenzo

With Antegren Launch Expected, Biogen Idec Tops 2Q Estimates

July 29, 2004

By Aaron Lorenzo

MannKind IPO Prices Within Range; Shares Close Higher

July 29, 2004

By Aaron Lorenzo

Specialty Pharma Firm Auxilium Raises $41.25M In Initial Offering

July 26, 2004

By Aaron Lorenzo

Aranesp, Enbrel, Neulasta Sales Drive Amgen To Beat Estimates

July 26, 2004

By Aaron Lorenzo

Amgen Inc. turned in second-quarter adjusted earnings per share of 62 cents, topping consensus estimates and surging 27 percent higher than a year ago. (BioWorld Today)

Aranesp, Enbrel, Neulasta Sales Drive Amgen To Beat Estimates

July 26, 2004

By Aaron Lorenzo

Amgen Inc. turned in second-quarter adjusted earnings per share of 62 cents, topping consensus estimates and surging 27 percent higher than a year ago. (BioWorld Today)

Specialty Pharma Firm Auxilium Raises $41.25M In Initial Offering

July 26, 2004

By Aaron Lorenzo

Chiron, MedImmune, Serono Report Earnings For Quarter

July 23, 2004

By Aaron Lorenzo

Chiron, MedImmune, Serono Report Earnings For Quarter

July 23, 2004

By Aaron Lorenzo

AGY In-Licenses Clinical CNS Compound From M's Science

July 21, 2004

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...